Buy, Sell, Or Hold LLY Stock At $750?

Company Overview - Eli Lilly's stock (NYSE: LLY) experienced a decline of over 6% on January 14 due to slower than expected growth in obesity drug sales, leading to a downward adjustment of Q4 revenue forecast by 5% to $13.5 billion, which is $500 million below analysts' consensus estimate of $14 billion [1] - For the full year 2024, Eli Lilly projects revenues of $45 billion, indicating a 32% growth over 2023, but still falling short of the $45.4 billion consensus estimate [1] Future Outlook - Despite the recent stock decline, the company's outlook for 2025 is strong, with projected revenues between $58 billion and $61 billion, reflecting a 32% growth at the midpoint compared to the expected 2024 revenue [3] - Eli Lilly has a robust pipeline with drugs in clinical trials across various therapeutic areas, including a potential regulatory approval for a new weight-loss drug, orforglipron, expected next year [4] Market Performance - Eli Lilly has consistently outperformed the broader market over the past four years, with its stock generating better returns than the S&P 500 [5] - The current dip in LLY stock is viewed as an opportunity for long-term investors, with analysts estimating an average price target of $985, indicating over 30% upside from current levels [6]